Proteome SciencesLSE:PRM +11.92% Operating Margin % is -54.98% as of Dec. 2025. The stock has 6 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, Proteome Sciences ranks worse than 79.41% on this metric.
The historical rank and industry rank for Proteome Sciences's Operating Margin % or its related term are showing as below:
LSE:PRM'
s Operating Margin % Range Over the Past 10 Years
Min: -97.92 Med: -38.59 Max: 22.21
Current: -70.98
LSE:PRM's Operating Margin % is ranked worse than 79.41% of 204
companies
in the Medical Diagnostics & Research industry
Industry Median: -3.195
vs LSE:PRM: -70.98
Proteome Sciences's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
Proteome Sciences Operating Margin % Related Terms
Proteome Sciences Operating Margin % Historical Data
* Premium members only.
The historical data trend for Proteome Sciences's Operating Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:PRM vs TMO, DHR, IDXX: Operating Margin % Comparison
For the Diagnostics & Research subindustry, Proteome Sciences's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Proteome Sciences Operating Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Proteome Sciences's Operating Margin % distribution charts can be found below:
* The bar in red indicates where Proteome Sciences's Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Proteome Sciences's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Proteome Sciences (LSE:PRM) has a Operating Margin % of -54.98% as of Dec. 2025. Operating margin is the ratio of total operating income to net sales. View historical data on Proteome Sciences and its competitors. According to the industry distribution chart, Proteome Sciences ranks #162 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 79.4%.
Is Proteome Sciences' Operating Margin % too high?
Proteome Sciences' current Operating Margin % is -54.98%. Based on the distribution chart, Proteome Sciences ranks #162 out of 204 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does Proteome Sciences' Operating Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Proteome Sciences ranks #162 out of 204 companies for Operating Margin %. This places Proteome Sciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Medical Diagnostics & Research company?
A good Operating Margin % depends on the Medical Diagnostics & Research industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Proteome Sciences and its competitors. Proteome Sciences's current Operating Margin % is -54.98%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Proteome Sciences stock overvalued right now?
Based on GuruFocus' analysis, Proteome Sciences (LSE:PRM) is currently considered Modestly Undervalued. The stock's GF Value™ is £0.02, compared to a current price of £0.02 — trading 15.5% below its estimated fair value. The current Operating Margin % is -54.98%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Proteome Sciences (LSE:PRM), the current Operating Margin % is -54.98% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Proteome Sciences PLC is engaged in protein biomarker research and development. The company is a provider of contract research services for the identification, validation and application of protein biomarkers. The company's only reportable segment is the sale of goods and biomarker services. The company generates maximum revenue from the TMT product and end customer sales-based royalties. Geographically, it has a presence in the United States, the United Kingdom, the European Union, and Others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:PRM has been successfully added to your 